N-Hydroxy-nor-L-arginine
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2012 (NCT02009527)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Arginase-1INHIBITOR
ARG1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- (2s)-2-amino-4-(((hydroxyamino)iminomethyl)amino)butanoic acid
- (2s)-2-amino-4-(((hydroxyamino)iminomethyl)amino)butanoic acid
- n-hydroxy-nor-arginine
- n-hydroxy-nor-arginine
- n-hydroxy-nor-arginine
- n-hydroxy-nor-l-arginine
- n-hydroxy-nor-l-arginine
- nomega-hydroxy-nor-l-arginine
- nomega-hydroxy-nor-l-arginine
- nor-noha
- nor-noha
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02009527 | Phase 1 | Jan 1, 2012 | Karolinska Institute |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Karolinska Institute | Academic/Hospital | 1 | 1 | 1 | 2012 |
1 organizations
Page 1 / 1